Gene: AR ×
Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs137852593
rs137852593
AR
0.040 GeneticVariation BEFREE R726L androgen receptor mutation is uncommon in prostate cancer families in the united states. 12539229

2003
dbSNP: rs137852593
rs137852593
AR
0.040 GeneticVariation BEFREE R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected. 14665948

2004
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis. 21383160

2011
dbSNP: rs976306779
rs976306779
AR
0.020 GeneticVariation BEFREE A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated. 15474988

2005
dbSNP: rs1057519864
rs1057519864
AR
0.020 GeneticVariation BEFREE A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509-treated patients with progressive disease. 23779130

2013
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR). 23813737

2013
dbSNP: rs139756052
rs139756052
AR
0.010 GeneticVariation BEFREE Additional studies will be required to define the frequency and contribution of the AR (A1675T) allele to early-onset and/or familial PCa in African Americans. 20173765

2010
dbSNP: rs968098233
rs968098233
AR
0.010 GeneticVariation BEFREE Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished. 15919721

2005
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A. 18007998

2007
dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17. 11571725

2001
dbSNP: rs137852569
rs137852569
AR
0.050 GeneticVariation BEFREE Conversely, no association was observed between prostate carcinoma risk and the other polymorphisms studied as follow: the CAG repeat in exon 1 of AR, the (TA)n dinucleotide repeat polymorphism in the 3' untranslated region, and the A49T or V89L substitutions in SDR5A2, the single base pair (bp) (a T to C transition) polymorphism that creates an additional Sp1-type (CCACC box) promoter site in CYP17. 11571725

2001
dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002
dbSNP: rs137852569
rs137852569
AR
0.050 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE Given the differential binding capacity and the favorable radioactivity pattern, (18) F-RB390 represents the portrayal of the first imaging ligand with predictive potential for mutant T877A-AR in prostate cancer for guiding therapy.Prostate 75:348-359, 2015.© 2014 Wiley Periodicals, Inc. 25358634

2015
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE Here, we demonstrate that genistein, a soy phytoestrogen binds to both the wild and the Thr877Ala (T877A) mutant types of AR competitively with androgen, nevertheless, it exerts a pleiotropic effect on PCa cell proliferation and AR activity depending on the mutational status of the AR. 24167630

2013
dbSNP: rs1034866440
rs1034866440
AR
0.050 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011
dbSNP: rs137852569
rs137852569
AR
0.050 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011
dbSNP: rs137852571
rs137852571
AR
0.010 GeneticVariation BEFREE In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met. 12507906

2003
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer. 19856921

2009
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms. 24874833

2014
dbSNP: rs777787518
rs777787518
AR
0.010 GeneticVariation BEFREE MDA prostate cancer 118a and MDA prostate cancer 118b cells carry a mutated β-catenin at codon 32 (D32G). 22298898

2012
dbSNP: rs976306779
rs976306779
AR
0.020 GeneticVariation BEFREE Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy. 18452169

2008
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen. 17312014

2007
dbSNP: rs864622007
rs864622007
AR
0.030 GeneticVariation BEFREE Our results indicate that the specific amino acid residue at position 701, its interaction with the backbone of Ser(778), and the steroidal 17alpha-hydroxyl group of the ligand are all important for the distinct transcriptional responses to progesterone and cortisol of AR mutants, including the prostate cancer mutant L701H. 20007693

2010
dbSNP: rs137852578
rs137852578
AR
0.100 GeneticVariation BEFREE Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups. 25409505

2014